Kenneth R Cooke, M.D.

  • Herman and Walter Samuelson Professor of Oncology
  • Professor of Oncology


Bone Marrow Failure, Bone Marrow Transplant, Haploidentical Bone Marrow Transplant, Medical Oncology, Pediatric Cancer, Pediatric Oncology more

Research Interests

Inflammatory mechanisms responsible for endothelial activation and injury after allogeneic BMT. Soluble and cellular effector mechanisms that contribute to non-infection lung injury and graft-versus-host disease in both the acute and chronic settings. more

Request an Appointment

Insurance Information

Main Phone

Outside of Maryland & Washington D.C.

Request Appointment

International Patients

Request Appointment


The Johns Hopkins Hospital (Main Entrance)

Appointment Phone: 410-955-8751
1800 Orleans St.
The Charlotte R. Bloomberg Children's Center Building, 11th Floor
Baltimore, MD 21287 map
Phone: 443-287-4959


Dr. Cooke is Director of the Johns Hopkins Kimmel Cancer Center’s Pediatric Bone Marrow Transplantation Program. Prior to his appointment at Johns Hopkins, Dr. Cooke headed the Pediatric Blood and Marrow Transplantation Program at Rainbow Babies and Children’s Hospital, and University Hospitals Case Medical Center, in Cleveland, Ohio. He also co-directed the Hematologic Disorders Program of the Case Comprehensive Cancer Center at Case Western Reserve University.

A nationally recognized transplantation immunology expert, Dr. Cooke focuses primarily on new strategies to prevent and treat graft-vs-host disease and lung complications following blood and bone marrow transplantation. His research efforts have been recognized by the Leukemia and Lymphoma Society and the American Society of Clinical Investigation. In addition to his younger patients, Dr. Cooke also cares for adolescents and young adults. more


  • Herman and Walter Samuelson Professor of Oncology
  • Director, Pediatic Blood and Marrow Transplantation Program
  • Professor of Oncology

Departments / Divisions

Centers & Institutes



  • MD; Rutgers - Robert Wood Johnson Medical School (1990)


  • Pediatrics; Children's Hospital of Philadelphia (1993)


  • Dana-Farber Cancer Institute (1996)

Research & Publications

Clinical Trial Keywords

Bone Marrow Transplantation, acute and chronic pulmonary dysfunction and graft-vs-host disease that occurs after BMT.

Clinical Trials

Bone Marrow Transplant

Selected Publications

Cooke KR, Gerbitz A, Crawford JM, Teshima T, Hill GR, Tesolin A, Rossignol DP, Ferrara JLM. LPS antagonism reduces graft-versus-host disease and preserves graft-versus-leukemia activity after experimental bone marrow transplantation.  J Clin Invest 2001; 107: 1581-1589.

Hildebrandt GC, Olkiewicz KM, Corrion LA, Chang Y, Clouthier S, Liu C, Cooke KR. Donor-derived tumor necrosis factor-alpha regulates pulmonary chemokine expression and the development of idiopathic pneumonia syndrome after allogeneic bone marrow transplantation. Blood 2004; 104: 586-593.

Yanik GA, Ho V, Levine JL, White E, Braun T, Antin J, Ferrara JLM, Cooke KR. The impact of soluble tumor necrosis factor receptor: etanercept on the treatment of idiopathic pneumonia syndrome following allogeneic stem cell transplantation. Blood 2008; 112:3073-81. PMCID 3045267.

Schlatzer DM, Dazard JE, Ewing RM, Ilchenko S, Rana G, Yanik G, Chance MR, Cooke KR. Human biomarker discovery and predictive models for disease progression for idiopathic pneumonia syndrome following allogeneic stem cell transplantation. Molec Cellular Proteomics 2012; 11: M111.015479. PMCID 3433920.

Yanik GA, Grupp SA, Pulsipher MA, Levine JE, Schulz KR, Wall DA, Langholz B, Dvorak CC, Alangaden K, Goyal RK, White ES, Collura JM, Skeens MA, Eid S, Pierce EM, Cooke KR, TNF-receptor inhibitor therapy for the treatment of children with idiopathic puenmonia syndrome. A joint Pediatric Blood and Marrow Transplant Consortium and Children’s Oncology Group Study (ASCT0521). Biol Blood Marrow Transplant 2015; 21(1): 67-73. PMCID 4286345.

Patient Ratings & Comments

The Patient Rating score is an average of all responses to physician related questions on the national CG-CAHPS Medical Practice patient experience survey through Press Ganey. Responses are measured on a scale of 1 to 5, with 5 being the best score. Comments are also gathered from our CG-CAHPS Medical Practice Survey through Press Ganey and displayed in their entirety. Patients are de-identified for confidentiality and patient privacy.

Is this you? Edit Profile
back to top button